On the enzymic defects in hereditary tyrosinemia
- PMID: 270706
- PMCID: PMC432003
- DOI: 10.1073/pnas.74.10.4641
On the enzymic defects in hereditary tyrosinemia
Abstract
The activity of the enzyme porphobilinogen synthase (EC 4.2.1.24) in erythrocytes from patients with hereditary tyrosinemia was less than 5% of that in a control group and the activity in liver tissue was less than 1% of the reported normal activity. Urine from patients with hereditary tyrosinemia contained an inhibitor that was isolated and identified as succinylacetone (4,6-dioxoheptanoic acid) by gas/liquid chromatography-mass spectrometry. Fresh urine samples contained succinylacetoacetate (3,5-dioxooctanedioic acid) as well as succinylacetone. The inhibition of porphobilinogen synthase explains the high excretion of 5-aminolevulinate observed in hereditary tyrosinemia. Succinylacetone and succinylacetoacetate presumably originate from maleylacetoacetate or fumarylacetoacetate, or both, and their accumulation indicates a block at the fumarylacetoacetase (EC 3.7.1.2) step in the degradation of tyrosine. We suggest that the severe liver and kidney damage in hereditary tyrosinemia may be due to the accumulation of these tyrosine metabolites and that the primary enzyme defect in hereditary tyrosinemia may be decreased activity of fumarylacetoacetase.
Similar articles
-
Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia.Clin Chim Acta. 1982 Aug 4;123(1-2):93-9. doi: 10.1016/0009-8981(82)90117-6. Clin Chim Acta. 1982. PMID: 7116642
-
Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone.J Clin Invest. 1983 Mar;71(3):625-34. doi: 10.1172/jci110809. J Clin Invest. 1983. PMID: 6826727 Free PMC article.
-
Biochemical studies on the enzymatic deficiencies in hereditary tyrosinemia.Clin Chim Acta. 1983 Oct 31;134(1-2):129-41. doi: 10.1016/0009-8981(83)90191-2. Clin Chim Acta. 1983. PMID: 6652907
-
Hereditary tyrosinemia type I--an overview.Scand J Clin Lab Invest Suppl. 1986;184:27-34. Scand J Clin Lab Invest Suppl. 1986. PMID: 3296130 Review.
-
Diagnosis and management of tyrosinemia type I.Curr Opin Pediatr. 1995 Dec;7(6):726-32. doi: 10.1097/00008480-199512000-00017. Curr Opin Pediatr. 1995. PMID: 8776026 Review.
Cited by
-
Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus.Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1363-7. doi: 10.1073/pnas.89.4.1363. Proc Natl Acad Sci U S A. 1992. PMID: 1741389 Free PMC article.
-
Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15.Am J Hum Genet. 1991 Mar;48(3):525-35. Am J Hum Genet. 1991. PMID: 1998338 Free PMC article.
-
Action of the phosphonic analogue of tyrosine and of other tyrosine derivatives on rat liver tyrosine aminotransferase.Amino Acids. 1993 Feb;5(1):33-7. doi: 10.1007/BF00806190. Amino Acids. 1993. PMID: 24190642
-
Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.J Inherit Metab Dis. 2008 Dec;31 Suppl 2:S223-5. doi: 10.1007/s10545-008-0807-z. Epub 2008 May 20. J Inherit Metab Dis. 2008. PMID: 18500574
-
Tyrosinemia type I: a clinico-laboratory case report.Indian J Pediatr. 2004 Oct;71(10):929-32. doi: 10.1007/BF02830839. Indian J Pediatr. 2004. PMID: 15531838
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases